If anemia is not corrected after adequate iron supplementation, treatment with erythropoiesis-stimulating agents (ESAs) has demonstrated remarkable efficacy in correcting the Hb levels, reducing the requirement for blood transfusions, hospital admissions, and overall mortality [9,17-19]. This evidence concerns the gene GSTM1 and anemia.